Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug582 | Biospecimen Collection Wiki | 0.41 |
| drug3181 | Quality-of-Life Assessment Wiki | 0.32 |
| drug3193 | Questionnaire Administration Wiki | 0.25 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004417 | Dyspnea NIH | 0.21 |
| D009369 | Neoplasms, NIH | 0.12 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002098 | Respiratory distress HPO | 0.21 |
| HP:0002664 | Neoplasm HPO | 0.12 |
Navigate: Correlations HPO
There are 2 clinical trials
The general aim of this study is to estimate the rate of disease progression for adults testing positive for SARS-CoV-2. The primary endpoint for this study and the basis for sample size is hospitalization or death during the 28 day follow-up period. In some locations special facilities are being built/utilized for quarantine/public health reasons for those who are SARS-CoV-2 positive. Hospitalization is defined as a stay for at least 18 hours, irrespective of reason, at a hospital or one of these special facilities after study enrollment. Secondary outcomes include participant-reported health status and change in severity of dyspnoea.
Description: Outcome reported as the mean number of days from enrollment to hospitalization due to COVID-19.
Measure: Time to Hospitalization Time: 28 daysDescription: Outcome reported as the mean number of days from enrollment to expiration (death) due to COVID-19.
Measure: Time to Expiration Time: 28 daysDescription: Outcome reported as the percent of participants who expire due to COVID-19 at 7 days post enrollment.
Measure: Rate of Death at 7 Days Time: 7 daysDescription: Outcome reported as the percent of participants who expire due to COVID-19 at 14 days post enrollment.
Measure: Rate of Death at 14 Days Time: 14 daysDescription: Outcome reported as the percent of participants who expire due to COVID-19 at 28 days post enrollment.
Measure: Rate of Death at 28 Days Time: 28 daysDescription: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 7 days post enrollment.
Measure: Rate of Hospitalization at 7 Days Time: 7 daysDescription: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 14 days post enrollment.
Measure: Rate of Hospitalization at 14 Days Time: 14 daysDescription: Outcome reported as the percent of participants who are hospitalized due to COVID-19 at 28 days post enrollment.
Measure: Rate of Hospitalization at 28 Days Time: 28 daysDescription: Outcome reported as the percent of participants who are in excellent or very good health at 7 days post enrollment.
Measure: Participant Health at 7 Days Time: 7 daysDescription: Outcome reported as the percent of participants who are in excellent or very good health at 14 days post enrollment.
Measure: Participant Health at 14 Days Time: 14 daysDescription: Outcome reported as the percent of participants who are in excellent or very good health at 28 days post enrollment.
Measure: Participant Health at 28 Days Time: 28 daysDescription: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 7 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 7 Days Time: 7 DaysDescription: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 14 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 14 Days Time: 14 DaysDescription: The Modified Borg Dyspnea scale (MBDS) contains 12 numeric values which designate the severity of dyspnea symptoms (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10). Higher scores indicate greater dyspnea severity. Outcome is reported as the mean MBDS score at 28 days post enrollment.
Measure: Modified Borg Dyspnea Scale at 28 Days Time: 28 DaysThis study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.
Description: Distinguish the likelihood of severe COVID19 (for example, requiring hospitalization, requiring intensive care unit [ICU] treatment or requiring a ventilator) and death due to COVID-19 for patients with versus without the factor. Among subgroups of at least 50 patients, evaluate using chi-square tests as well as death and hospitalization rates.
Measure: Patient variables (factors) associated with severe acute respiratory syndrome (SARS) coronavirus 2 (COVID-19) severity Time: Up to 2 yearsDescription: Describe the degree to which COVID-19 interrupts, delays, or otherwise alters cancer treatment for pediatric patients and subgroups of adult patients defined by cancer type and/or treatment modality. Describe the association between changes in cancer therapy and clinical outcomes. Evaluate association of COVID-19 with outcome by comparison to historical controls in subgroups of at least 50 patients using log rank tests to assess time to survival event.
Measure: Effects of COVID-19 on cancer therapy and association with clinical outcomes Time: Up to 2 yearsDescription: Will be measured using items from the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 Profile.
Measure: Physical health (patient-reported health-related quality of life) Time: Up to 2 yearsDescription: Analysis will include time to development of antibodies, prevalence of cytokine abnormalities, and genome-wide association study (GWAS) to define genetic polymorphisms associated with severe COVID-19 disease/mortality.
Measure: Collection of blood specimens for future biomarker studies Time: Up to 2 yearsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports